Regeneron Pharmaceuticals, Inc. (REGN) Earns Outperform Rating from Sanford C. Bernstein

Regeneron Pharmaceuticals, Inc. (REGN) Earns Outperform Rating from Sanford C. Bernstein


's stock had its "outperform" rating reissued by research analysts at Sanford C. Bernstein in a research note issued on Thursday. They presently have a $410.00 price objective on the biopharmaceutical company's stock, down from their previous price objective of $420.00.



from Biotech News